Here is your roundup of what made top news in 2016!
LENSAR Inc. announced its filing of a Chapter 11 bankruptcy petition on Dec. 19 to reduce its debt, strengthen its balance sheet, and strengthen its platform for future growth, according to a press release from the company.
Laser techniques have fundamentally changed the cataract surgery landscape. New, versatile platforms have made surgery safer and provided superior clinical outcomes precisely, consistently and predictably.
Trifocal IOLs can provide good uncorrected vision at near, intermediate, and far. Outcomes in a series of 30 patients show that a toric version of a trifocal IOL (AT Lisa tri 939MP, Carl Zeiss Meditec) delivers those benefits for patients with > 1 D of corneal astigmatism.
In a timely talk at Refractive Surgery Subspecialty Day 2016, Sunil Shah, MD, made a case for why refractive surgeons might want to consider this minimally-invasive corneal refractive procedure.
An implantable corneal inlay recently approved by the FDA gives ophthalmologists a new choice in treating presbyopia.
Reductions in vision correlate with lower literacy scores on standardised tests, a new study showed.
It has been a history-making week for the ophthalmic world, and the FDA approval of the first IOL with extended range of vision (Tecnis Symfony IOL, Abbott) has only added one more reason for celebration.
The U.S. IDE clinical trial of the investigational extended range of vision IOL (Model ZXR00; Tecnis Symfony Extended Range of Vision IOL, Abbott Medical Optics) found that the implant delivered a full range of uncorrected vision and minimized or eliminated the need for spectacle wear in most patients.
A topical treatment that breaks apart disulfide bonds between crystalline lens proteins was shown to increase accommodative amplitude and improve near visual acuity in a randomized, placebo-controlled clinical trial.